Non-Hodgkin lymphoma and changes in hemostatic markers
General Medicine, 2026, 28(1), 13-19.
S. Stoencheva1,3, K. Sapunarova2,4, D. Mileva5
1Department of Clinical Laboratory, Faculty of Medicine, Medical University – Plovdiv
2Section of Hematology, First Department of Internal Diseases, Faculty of Medicine, Medical University – Plovdiv
3Clinical Laboratory, University Hospital “Sv. Georgi” – Plovdiv
4Department of Clinical Hematology, University Hospital “Sv. Georgi” – Plovdiv
5Department of Urology and General Practice, Faculty of Medicine, Medical University – Plovdiv
Abstract. Thrombosis is a common complication in patients with hematological malignancies. The aim of the study is to investigate changes in the laboratory parameters for coagulation and fibrinolysis – tissue factor (TF), prothrombin fragment (F1+2), thrombin-antithrombin complex (TAT), fibrinogen (Fib), antithrombin III (AT III) and D-dimer in patients with non-Hodgkin lymphoma on systemic therapy. Materials and Methods: The current investigation included 40 patients with non-Hodgkin lymphoma and a control group of 65 healthy volunteers. We measured plasma levels of TF, F1+2, ТАТ, fibrinogen, AT III and D-dimer baseline, before therapy (visit 1), monitoring response to therapy (visit 2), and after completion of therapy (visit 3). These parameters were investigated only once in healthy controls. TF, F1+2 and TAT were measured by ELISA. D-dimer, AT III and fibrinogen were measured by automated coagulation system Sysmex CS 2000i. Results: Patients with non-Hodgkin lymphoma have significantly higher levels of TF, F1+2, ТАТ, fibrinogen and D-dimer than the control group, while AT III activity was significantly lower (P < 0.001). F1+2, ТАТ, TF and D-dimer decreased during the follow-up, and baseline levels were significantly higher vs. visit 2 and visit 3 (P < 0.05). Conclusion: Systemic therapy significantly influences the dynamics of hemostatic markers. Patients with non-Hodgkin lymphoma are at high risk of thrombosis, and antithrombotic prophylaxis could be considered.
Key words: hemostasis, thrombosis, non-Hodgkin lymphoma
Address for correspondence: Snezhana Stoencheva, e-mail: snezhana.stoencheva@mu-plovdiv.bg, https://orcid.org/0000-0002-4468-2133